Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.
Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.
© 2023 LBNN - All rights reserved.